New hope for sarcoma patients after chemo fails
NCT ID NCT05106777
First seen Jun 11, 2026 · Last updated Jun 12, 2026 · Updated 1 time
Summary
This study tests a drug called surufatinib in people with advanced bone or soft tissue sarcoma whose cancer has not responded to standard chemotherapy. The goal is to see if the drug can slow or stop tumor growth. About 47 participants aged 14 to 70 will receive the drug and be monitored for safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-Sen Univerisity
Guangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.